Company intelligence / Profile preview

CelineTx

Ownership: Private
Development stage: Other

Overview

CelineTx is an early-stage biotechnology company focused on developing next-generation cell therapies for oncology and autoimmune diseases. The company leverages a proprietary cell engineering platform designed to enhance the persistence and efficacy of CAR-T and NK cell therapies. By optimizing the cellular microenvironment and genetic architecture of its candidates, CelineTx aims to overcome common limitations of current adoptive cell transfer treatments, such as exhaustion and limited infiltration into solid tumors. Their current pipeline is focused on targeting validated antigens in hematologic malignancies while expanding into broader therapeutic applications.

Therapeutic areas: OncologyImmunology
Modalities: Cell therapyCAR-T cell therapyNK cell therapy
Industry: Biotech

Beyond the preview

Go deeper on CelineTx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CelineTx.

Explore the full profile